Entero Therapeutics, Inc. (NASDAQ:GRDX) Short Interest Down 41.2% in June

Entero Therapeutics, Inc. (NASDAQ:GRDX) was the target of a significant decline in short interest in the month of June. As of June 15th, there was short interest totaling 43,189 shares, a decline of 41.2% from the May 31st total of 73,503 shares. Currently, 0.7% of the shares of the stock are sold short. Based on an average trading volume of 123,990 shares, the days-to-cover ratio is currently 0.3 days.

Entero Therapeutics Price Performance

NASDAQ:GRDX traded down $0.24 during mid-day trading on Wednesday, hitting $4.45. The company’s stock had a trading volume of 17,569 shares, compared to its average volume of 125,454. The firm has a market cap of $29.59 million, a P/E ratio of -2.37 and a beta of 1.80. Entero Therapeutics has a fifty-two week low of $1.08 and a fifty-two week high of $6.93. The company has a fifty day simple moving average of $4.29.

Entero Therapeutics (NASDAQ:GRDX) last released its quarterly earnings data on Wednesday, May 27th. The company reported ($0.82) earnings per share for the quarter. The business had revenue of $0.04 million during the quarter.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Entero Therapeutics stock. DRW Securities LLC acquired a new stake in shares of Entero Therapeutics, Inc. (NASDAQ:GRDX) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 48,623 shares of the company’s stock, valued at approximately $227,000. DRW Securities LLC owned 1.45% of Entero Therapeutics as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 12.30% of the company’s stock.

Entero Therapeutics Company Profile

Entero Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of targeted and orally delivered therapies for the treatment of patients with gastrointestinal diseases. The company’s pipeline candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides, currently under Phase 2 studies; and capeserod, a selective 5-HT4 receptor partial agonist under Phase 1 studies for the treatment of gastroparesis.